Serum neutralization of SARS coronavirus 2 Omicron sublineages BA.1 and BA.2 and cellular immune responses 3 months after booster vaccination

被引：1

作者：

Alidjinou, Enagnon Kazali ^{[1
]}

Demaret, Julie ^{[2
]}

Corroyer-Simovic, Benedicte ^{[3
]}

Vuotto, Fanny ^{[4
]}

Miczek, Sophie ^{[5
]}

Labreuche, Julien ^{[6
]}

Goffard, Anne ^{[7
]}

Trauet, Jacques ^{[2
]}

Lupau, Daniela ^{[2
]}

Dendooven, Arnaud ^{[2
]}

Huvent-Grelle, Dominique ^{[3
]}

Podvin, Juliette ^{[3
]}

Dreuil, Daniel ^{[3
]}

Faure, Karine ^{[4
]}

Deplanque, Dominique ^{[8
]}

Bocket, Laurence ^{[1
]}

Duhamel, Alain ^{[9
]}

Sobaszek, Annie ^{[10
]}

Hober, Didier

Hisbergues, Michael ^{[11
]}

Puisieux, Francois

Autran, Brigitte ^{[12
,13
]}

Yazdanpanah, Yazdan ^{[14
]}

Labalette, Myriam ^{[2
]}

Lefevre, Guillaume ^{[2
]}

机构：

[1] Univ Lille, CHU Lille, Lab Virol, Lille, France

[2] Univ Lille, Inst Immunol, CHU Lille, INFINITE Inst Translat Res Inflammat Inserm, Lille, France

[3] Univ Lille, Hop Geriatr Bateliers, CHU Lille, Pole Geriatr, Lille, France

[4] CHU Lille, Dept Malad Infectieuses, Lille, France

[5] CHU Lille, Mdecine & Sante Travail, Lille, France

[6] CHU Lille, Dept Biostat, Lille, France

[7] Univ Lille, Inst Pasteur Lille, CIIL U1019,CNRS,Inserm,CHU Lille, Ctr Infect & Immunite Lille Ctr Infect & Immunite, Lille, France

[8] Univ Lille, CIC Clin Invest Ctr 1403, Inserm, CHU Lille, F-59000 Lille, France

[9] Univ Lille, CHU Lille, EA 2694 Sante Publ Epidemiol & Qual Soins, Lille, Hauts De France, France

[10] Univ Lille, CHU Lille, Med & Sante Travail, ULR 4483, Lille, France

[11] Univ Lille, Ctr Ressources Biol, CHU Lille, Lille, France

[12] Sorbonne Univ, Paris, France

[13] Ctr Rech Immun Malad Infectieuses, UMR S Inserm, UPMC 1135, Paris, France

[14] Hop Bichat Claude Bernard, Infect Dis Dept, INSERM, IAME, Paris, France

来源：

CLINICAL MICROBIOLOGY AND INFECTION | 2023年 / 29卷 / 02期

关键词：

COVID-19; Neutralizing antibodies; Omicron; T cells;

D O I：

10.1016/j.cmi.2022.10.014

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

Objectives: We investigated serum neutralizing activity against BA.1 and BA.2 Omicron sublineages and T cell response before and 3 months after administration of the booster vaccine in healthcare workers (HCWs). Methods: HCWs aged 18-65 years who were vaccinated and received booster doses of the BNT162b2 vaccine were included. AntieSARS coronavirus 2 IgG levels and cellular response (through interferon gamma ELISpot assay) were evaluated in all participants, and neutralizing antibodies against Delta, BA.1, and BA.2 were evaluated in participants with at least one follow-up visit 1 or 3 months after the administration of the booster dose. Results: Among 118 HCWs who received the booster dose, 102 and 84 participants attended the 1-month and 3-month visits, respectively. Before the booster vaccine dose, a low serum neutralizing activity against Delta, BA.1, and BA.2 was detectable in only 39/102 (38.2%), 8/102 (7.8%), and 12/102 (11.8%) participants, respectively. At 3 months, neutralizing antibodies against Delta, BA.1, and BA.2 were detected in 84/84 (100%), 79/84 (94%), and 77/84 (92%) participants, respectively. Geometric mean titres of neutralizing antibodies against BA.1 and BA.2 were 2.2-fold and 2.8-fold reduced compared with those for Delta. From 1 to 3 months after the administration of the booster dose, participants with a recent history of SARS coronavirus 2 infection (n = 21/84) had persistent levels of S1 reactive specific T cells and neutralizing antibodies against Delta and BA.2 and 2.2-fold increase in neutralizing antibodies against BA.1 (p 0.014). Conversely, neutralizing antibody titres against Delta (2.5-fold decrease, p < 0.0001), BA.1 (1.5-fold, p 0.02), and BA.2 (2-fold, p < 0.0001) declined from 1 to 3 months after the administration of the booster dose in individuals without any recent infection. Discussion: The booster vaccine dose provided significant and similar response against BA.1 and BA.2 Omicron sublineages; however, the immune response declined in the absence of recent infection. Enagnon Kazali Alidjinou, Clin Microbiol Infect 2023;29:258.e1-258.e4 (c) 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

引用

页码：258e1 / 258e4

页数：4

共 17 条

[1]

[Anonymous], SARS-CoV-2 Variants-Omicron BA.1-Stanford Coronavirus Antiviral & Resistance Database (CoVDB)

[2] Severe SARS-CoV-2 patients develop a higher specific T-cell response [J].

Demaret, Julie ;

Lefevre, Guillaume ;

Vuotto, Fanny ;

Trauet, Jacques ;

Duhamel, Alain ;

Labreuche, Julien ;

Varlet, Pauline ;

Dendooven, Arnaud ;

Stabler, Sarah ;

Gachet, Benoit ;

Bauer, Jules ;

Prevost, Brigitte ;

Bocket, Laurence ;

Alidjinou, Enagnon Kazali ;

Lambert, Marc ;

Yelnik, Cecile ;

Meresse, Bertrand ;

Dubuquoy, Laurent ;

Launay, David ;

Dubucquoi, Sylvain ;

Montaigne, David ;

Woitrain, Eloise ;

Maggiotto, Francois ;

Bou Saleh, Mohamed ;

Top, Isabelle ;

Elsermans, Vincent ;

Jeanpierre, Emmanuelle ;

Dupont, Annabelle ;

Susen, Sophie ;

Brousseau, Thierry ;

Poissy, Julien ;

Faure, Karine ;

Labalette, Myriam .

CLINICAL & TRANSLATIONAL IMMUNOLOGY, 2020, 9 (12)

[3] Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2 [J].

Evans, John P. ;

Zeng, Cong ;

Qu, Panke ;

Faraone, Julia ;

Zheng, Yi-Min ;

Carlin, Claire ;

Bednash, Joseph S. ;

Zhou, Tongqing ;

Lozanski, Gerard ;

Mallampalli, Rama ;

Saif, Linda J. ;

Oltz, Eugene M. ;

Mohler, Peter J. ;

Xu, Kai ;

Gumina, Richard J. ;

Liu, Shan-Lu .

CELL HOST & MICROBE, 2022, 30 (08) :1093-+

[4]

Garcia-Beltran WF, 2022, CELL, V185, P457, DOI [10.1016/j.cell.2021.12.033, 10.1101/2021.12.14.21267755]

[5]

Jacobsen H, 2021, medRxiv, DOI [10.1101/2021.12.21.21267898, 10.1101/2021.12.21.21267898, DOI 10.1101/2021.12.21.21267898]

[6]

Lyngse F.P., 2022, medRxiv, DOI DOI 10.1101/2022.01.28.22270044

[7]

Muecksch F., 2022, bioRxiv, DOI DOI 10.1101/2022.02.14.480394

[8] Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations [J].

Muecksch, Frauke ;

Weisblum, Yiska ;

Barnes, Christopher O. ;

Schmidt, Fabian ;

Schaefer-Babajew, Dennis ;

Wang, Zijun ;

Lorenzi, Julio C. C. ;

Flyak, Andrew, I ;

DeLaitsch, Andrew T. ;

Huey-Tubman, Kathryn E. ;

Hou, Shurong ;

Schiffer, Celia A. ;

Gaebler, Christian ;

Da Silva, Justin ;

Poston, Daniel ;

Finkin, Shlomo ;

Cho, Alice ;

Cipolla, Melissa ;

Oliveira, Thiago Y. ;

Millard, Katrina G. ;

Ramos, Victor ;

Gazumyan, Anna ;

Rutkowska, Magdalena ;

Caskey, Marina ;

Nussenzweig, Michel C. ;

Bjorkman, Pamela J. ;

Hatziioannou, Theodora ;

Bieniasz, Paul D. .

IMMUNITY, 2021, 54 (08) :1853-+

[9] Serum Neutralization of SARS-CoV-2 Omicron BA.1 and BA.2 after BNT162b2 Booster Vaccination [J].

Pedersen, Rune M. ;

Bang, Line L. ;

Madsen, Lone W. ;

Sydenham, Thomas V. ;

Johansen, Isik S. ;

Jensen, Thoger G. ;

Justesen, Ulrik S. ;

Andersen, Thomas E. .

EMERGING INFECTIOUS DISEASES, 2022, 28 (06) :1274-1275

[10] Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination [J].

Perez-Then, Eddy ;

Lucas, Carolina ;

Monteiro, Valter Silva ;

Miric, Marija ;

Brache, Vivian ;

Cochon, Leila ;

Vogels, Chantal B. F. ;

Malik, Amyn A. ;

De la Cruz, Elena ;

Jorge, Aidelis ;

De los Santos, Margarita ;

Leon, Patricia ;

Breban, Mallery, I ;

Billig, Kendall ;

Yildirim, Inci ;

Pearson, Claire ;

Downing, Randy ;

Gagnon, Emily ;

Muyombwe, Anthony ;

Razeq, Jafar ;

Campbell, Melissa ;

Ko, Albert, I ;

Omer, Saad B. ;

Grubaugh, Nathan D. ;

Vermund, Sten H. ;

Iwasaki, Akiko .

NATURE MEDICINE, 2022, 28 (03) :481-+

← 1 2 →